The successful candidate will be a Scientist or Senior Scientist at the OHRI and hold an academic appointment with the uOttawa Faculty of Medicine. The OHRI is one of the foremost Canadian hospital-based research institutes, and one of Canada’s top centres for cancer research. Our research focuses on translating discovery and knowledge into better health. The Faculty of Medicine is the first and largest bilingual medical faculty in Canada, consisting of over 2,400 faculty members, including clinicians and researchers. It is one of uOttawa’s largest and most research-intensive faculties, which focuses on advancing, developing, and delivering cutting-edge patient care, medical research, and high-quality education to prepare future generations of academic researchers and healthcare professionals.
The successful candidate will be joining the OHRI/uOttawa at an exciting time when several collaborative initiatives and large-scale infrastructure projects are underway to significantly expand support for translational research. These include the Canadian Pandemic Preparedness Hub (CP2H), uOttawa’new Advanced Medical Research Centre, which will house the Ottawa Health Innovation Hub, and The Ottawa Hospital’s state-of-the-art new campus, which will be the most advanced hospital in Canada and a major centre for research and innovation. The new campus will be the home of the OHRI’s expanded Biotherapeutics Manufacturing Centre (BMC).
We are interested in attracting an internationally recognized leader in translational research with interests in the development of biotherapeutics for cancer (including immunotherapy), regenerative medicine, and/or infectious disease. The Chair’s mandate will be aligned with the OHRI/uOttawa vision of rapidly moving fundamental scientific discoveries into clinical application. They will take knowledge of new insights into disease mechanisms or new therapeutic targets and apply it to the development of treatments that can be tested in humans.
The Chair is expected to focus on bridging the gap between discovery and clinical use, ensuring that novel therapies are safe and effective for human patients. They should have an understanding and appreciation of the continuum of activities (including preclinical research, manufacturing, regulatory compliance, and clinical trials) that are needed to bring innovative discoveries to the marketplace. The selected candidate will have a track record of scientific leadership, which has been demonstrated by acquiring large-scale grants and catalyzing collaboration among scientists, clinicians, regulatory experts, and industrial partners.
Tier 1 Chairs, tenable for seven years and renewable once, are for outstanding researchers acknowledged by their peers as world leaders in their fields. For each Tier 1 Chair, the institution receives $200,000 annually for seven years. In addition to the government’s contribution, the uOttawa/OHRI will also provide the successful candidate with a competitive start-up package. Nominees for Tier 1 Chair positions must be full professors or associate professors who are expected to be promoted to the full professor level within one or two years of the nomination. Alternatively, if they come from outside the academic sector, nominees must possess the necessary qualifications to be appointed at these levels. New CRC nominees are also eligible for infrastructure support from the Canada Foundation for Innovation (CFI) to help acquire state-of-the-art equipment essential to their work.